[1]Li LS, Liu ZH. Epidemiologic date of renal disease from single unit in China: analysis based on 13,519 renal biopsies[J]. Kindey Int, 2004,66(3):920-923.
[2]Beck LH, Boneegio RG, Lambeau G, et al. M-type phospholipase A2 recepor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med,2009,361(2):11-21.
[3]Hofstra JM, Beck LH, Beck DM,et al.Anti- phospholipase A2 recepor antibodies correlate with clinical status in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2011,6(6):1286-1291.
[4]Hoxha E,Harendza S, Zahner G,et al.An immunofluorescence test for phospholipase A2 recepor antibodies and its clicinal usefulness in patients with membranous glomeruloneephritis[J]. Nephrol Dial Transplant,2011,26(8):2526-2532.
[5]Beck LH, Fervenza FC, Beck DM,et al.Rituximab-induced depletion of anti-PLA2R autobodies predictsresponsein membranous enphropathy[J]. J Am Soc Nephrol,2011,22(8):1543-1550.
[6]Debiec H, Ronco P. PLA2R autobodies and PLA2R glomerular deposits in membranous enphropathy[J]. N Engl J Med,2011,364(4):689-690.
[7]Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification erythematusus[J]. Arthritis Rheum,1982,25(11):1271-1277.
[8]Hochberg MC. Updating of the American College of Rheumatology revised criteria for the classification erythematusus[J]. Arthritis Rheum,1997,40(9):1725.
[9]Petri M, Orbai AM, Alarcon GS, et al.Derivation and validation of the lupus international collaborating clinic classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum,2012,64(8):2677-2686.
[10]Weening JJ, D Agati VD, Schwartz MM,et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kindey Int,2004,65(2):521-530.
[11]《中华内科杂志》编委会. 乙型肝炎病毒相关性肾炎座谈会纪要[J]. 中华内科杂志,1990, 29(9):519-521.
[12]Levey AS.Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med,2012,367(1):20-29.
[13]周广宇,金玲,于晶,等.成人膜性肾病患者血清抗PLA2R抗体与病情的相关性[J]. 中华肾脏病杂志,2012,28(2):111-114.
[14]林伟峰,李航,李雪梅,等.抗磷脂酶A2受体抗体与特发性膜性肾病的关系[J]. 中华内科杂志,2015,54(9):783-788.
[15]Oh YJ, Yang SH, Kim DK, et al.Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One,2013,8(4):e62151.
[16]Gunnarsson I, Schlumberger W, Ronnelid J. Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis[J]. Am J Kidney Dis,2012,59(4):585-586.
[17]Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy[J]. J Am Soc Nephrol,2011,22(6):1137-1143.
[18]Svobodova B, Honsova E, Ronco P, et al.Kidney biopsy is a sensitive tool forretrospective diagnosis of PLA2R-related membranous nephropathy[J]. Nephrol Dial Transplant,2013,28(7):1839-1844.
[19]Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renalbiopsies[J]. Mod Pathol, 2013,26(5):709-715.
[20]Hoxha E, Kneissler U, Stege G,et al.Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primarymembranous nephropathy [J]. Kindey Int,2012,82(7):797-804.
[21]Hofstra JM, Debiec H,Short CD, et al.Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012,23(10):1735-1743.
[22]钱玉珺, 左科,李世军,等.膜性肾病合并新月体形成的临床病理分析[N].医学研究生学报,2015, 28(12):1262-1267.
[23]陈幸, 蔡美顺,王梅.不典型膜性肾病患者血清M型磷脂酶A2受体抗体及肾组织IgG亚型分布的研究[J]. 中华肾脏病杂志,2014,30(6):406-412.
[1]金英,张炯,程震,等.硫普罗宁相关肾损害的临床病理特征并文献复习[J].医学研究与战创伤救治(原医学研究生学报),2020,22(3):239.[doi:10.3969/j.issn.1672-271X.2020.03.004]
JIN Ying,ZHANG Jiong,CHENG Zhen,et al.The clinical and pathological characteristics of tiopronin-induced nephropathy:a case report and literature review[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(03):239.[doi:10.3969/j.issn.1672-271X.2020.03.004]